New strategies for investigating antiestrogen action in breast cancer.
The major difference observed by us between estrogen and antiestrogen pathways in breast cancer cells occurs immediately after translocation. We have called the loss of nuclear receptor following estradiol administration "processing" and have hypothesized that is is a prerequisite for estrogen stimulation in breast cancer cells and that failure of processing relates to antiestrogen effects. In the very near future, monoclonal antibody technology could be used to dissect the processing of nuclear receptor and shed now light on the mechanism of antiestrogen action.
D000911:Antibodies, Monoclonal / Q000276:immunology; D001665:Binding Sites; D001943:Breast Neoplasms / Q000378:metabolism*; D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D000939:Epitopes; D004965:Estrogen Antagonists / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D011946:Receptors, Antigen / Q000276:immunology* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000276:immunology / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D000939:Epitopes; D004965:Estrogen Antagonists; D004967:Estrogens; D011946:Receptors, Antigen; D011960:Receptors, Estrogen